Rheumatoid Arthritis
Rheumatoid Arthritis
Rheumatoid Arthritis
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Rheumatoid</strong> <strong>Arthritis</strong><br />
June 6, 2011<br />
Deborah S. Collier, MD<br />
Rheumatology Unit<br />
Massachusetts General Hospital<br />
Harvard Medical School
I have<br />
no industry<br />
sponsorship or<br />
affiliations
Focus of today’s review<br />
• Overview<br />
• 7 questions for patient with RA to PCP
<strong>Rheumatoid</strong> <strong>Arthritis</strong>: Epidemiology<br />
• Systemic inflammatory arthritis than can also involve<br />
internal organs<br />
• Female: male ratio = 2.5:1<br />
• Prevalence ~ 1%, peak 30 – 55 years old<br />
• Genetic predisposition (HLA-DRB1)<br />
• Environmental risk factors: cigarette smoking, infection<br />
• Shortens life span, causes disability<br />
de Vries N, et al. <strong>Arthritis</strong> Rheum 2002 Apr;46(4):921-8. Pincus T, et al. J Rheumatol. 1989<br />
Klareskog L , et al. <strong>Arthritis</strong> Rheum. 2006;54:38-46. Pincus T, et al. J Rheumatol. 1987.
<strong>Rheumatoid</strong> <strong>Arthritis</strong>: Clinical Features<br />
• Symmetrical polyarthritis<br />
• Morning stiffness<br />
- Lasting ≥ 1 hour<br />
• <strong>Rheumatoid</strong> nodules<br />
• Limited range of motion<br />
• Extraarticular involvement:<br />
eye, lung, heart, muscle,<br />
vasculature
RA: Erosive <strong>Arthritis</strong>
<strong>Rheumatoid</strong> <strong>Arthritis</strong>: Treatment<br />
Then…<br />
…and Now
History of DMARD* Use in the United States<br />
Anti-IL6<br />
↓ T-cell activation<br />
Anti-CD20<br />
Tocilizumab<br />
Abatacept<br />
Rituximab<br />
Anti-TNF Etanercept, Infliximab, Adalimumab, Certolizumab, Golimumab<br />
Leflunomide<br />
Methotrexate<br />
Penicillamine<br />
Sulfasalazine<br />
Antimalarials<br />
Aspirin Cortisone<br />
Gold<br />
1900<br />
1940 1950 1960 1970 1980 1990 2000<br />
2010<br />
*DMARD = Disease Modifying Anti-Rheumatic Drug<br />
= biologic
<strong>Rheumatoid</strong> <strong>Arthritis</strong>: Treatment<br />
…from first suspicion in<br />
PCP’s office to optimal<br />
treatment by rheumatologist<br />
in 6-12 months…
7 RA questions from patient to PCP…<br />
• risk factors for RA<br />
• adverse effects of DMARDs (disease modifying antirheumatic<br />
drugs)<br />
• safety of immunizations in patients on DMARDs<br />
• Safety of biologics in patients with hepatitis
My mother has RA. Are there<br />
any life style changes that I can<br />
make to avoid getting it myself<br />
A. loose weight<br />
B. quit smoking<br />
C. keep immunizations up to date<br />
D. all of the above
My mother has RA. Are there<br />
any life style changes that I can<br />
make to avoid getting it myself<br />
A. lose weight<br />
B. quit smoking<br />
C. keep immunizations up to date<br />
D. all of the above
Smoking and RA<br />
- RR of developing RA = 1.4 for women who smoke >25 cigarettes a<br />
day, compared to non-smokers<br />
- In HLA-DRB4 (+) patients, RR of developing RA is 5.6 in smokers,<br />
compared to non-smokers<br />
- RA patients with > 25 pack year history are more likely to be seropositive,<br />
have nodules, have bony erosion<br />
- Risk of developing RA returns to baseline 10 years after quitting<br />
smoking<br />
Karlson, <strong>Arthritis</strong> Rheum 1999. Padyokuv, <strong>Arthritis</strong> Rheum 2004.<br />
Saag, Ann Rheum Dis 1997. Criswell, Am J Med 2002.
What are the risks of being on a<br />
biologic medication for RA
Toxicities of Biologics<br />
TNF’s, rituximab, adalimumab<br />
• Injection site/infusion reactions<br />
• Serious infections<br />
• Opportunistic infections (TB, fungal)<br />
• Malignancy<br />
Rituximab specific<br />
• Progressive multifocal leukoencephalopathy (PML)<br />
Anti-TNF specific<br />
• Demyelination (MS-like syndrome)<br />
• Drug-induced lupus<br />
• Congestive heart failure<br />
Ellerin, <strong>Arthritis</strong> Rheum. 2003.<br />
Mohan, <strong>Arthritis</strong> Rheum 2001.<br />
Kwon, Ann Intern Med 2003.
Serious Infections in Pt’s on Biologics<br />
Bacteria<br />
Streptococccus pneumoniae<br />
Listeria monocytogenes<br />
Mycobacteria<br />
Mycobacterium tuberculosis *<br />
Mycobacterium aviumintracellulare<br />
(MAC)<br />
Fungi<br />
Candida albicans<br />
Pneumocystis jiroveci<br />
Aspergillus fumigatus<br />
Histoplasma capsulatum<br />
Cryptococcus neoformans<br />
Coccidioides immitis<br />
* make sure pt is PPD (-)<br />
Ellerin, <strong>Arthritis</strong> Rheum. 2003.
I am on etanercept for my RA.<br />
Is it true that this drug can<br />
cause cancer<br />
You tell the patient:<br />
A.Anti-TNF’s are associated with definite risk of solid tumors<br />
B.Anti-TNF’s are associated with definite risk of skin cancer<br />
C.Anti-TNF’s are associated with definite risk of lymphoma<br />
D.Anti-TNF’s are associated with definite risk of leukemia
I am on etanercept for my RA.<br />
Is it true that this drug can<br />
cause cancer<br />
You tell the patient:<br />
A. anti-TNF’s are associated with definite risk of solid tumors<br />
B. anti-TNF’s are associated with definite risk of skin cancer<br />
C. anti-TNF’s are associated with definite risk of lymphoma<br />
D. anti-TNF’s are associated with definite risk of leukemia
Malignancy in RA patients on anti-TNF’s –<br />
Conflicting Data<br />
* RR of lymphoma in RA pt’s compared to general population is 2.0<br />
• melanomatous and non-melanomatous cancer increased in RA pt<br />
on anti-TNF, odds ratio 1.5 and 2.3 respectively 1<br />
• conflicting data on risk of lymphoma in RA pt on anti-TNF 2<br />
• conflicting data on risk of solid tumors in RA pt on anti-TNF 3<br />
1<br />
Wolfe, <strong>Arthritis</strong> Rheum. 2007. (53,000 pts)<br />
2<br />
Bongartz, JAMA. 2006. (3,500 pt’s – increased lymphoma risk)<br />
2<br />
Askling, Ann Rheum Dis. 2005. (53,000 pts – no increased lymphoma risk)<br />
3<br />
Geborek, Ann Rheum Dis. 2005 (800 pts – increased risk of solid tumors)<br />
3<br />
Bongartz, JAMA. 2006. (3,500 pts – increased risk of solid tumors)<br />
3<br />
Askling, Ann Rheum Dis. 2005 (53,000 pts – no increased risk of solid tumors)<br />
3<br />
Wolfe, <strong>Arthritis</strong> Rheum. 2007. (53,000 pts – no increased risk of solid tumors)
I am on infliximab for RA and am<br />
travelling to South America. Can I<br />
get the yellow fever vaccine
I am on infliximab for RA and am<br />
travelling to South America. Can I<br />
get the yellow fever vaccine<br />
NO!<br />
No live viral vaccines for patients on biologics:<br />
• yellow fever<br />
• MMR<br />
• zoster, varicella<br />
• oral polio<br />
• small pox
Immunization with biologic therapies in RA<br />
RECOMMENDED:<br />
• Tetanus<br />
• Diphtheria<br />
• Inactivated polio<br />
• Pneumococcal<br />
• Influenza<br />
• Hepatitis B<br />
CONTRAINDICATED:<br />
• Oral polio *<br />
• Yellow fever<br />
• MMR<br />
• Varicella<br />
• Small pox *<br />
• Zoster<br />
* Should not be used in household<br />
contacts, avoid contact for 1 month
I am on methotrexate and<br />
hydroxychloroquine for RA. Are there<br />
any vaccines I cannot get
I am on methotrexate and<br />
hydroxychloroquine for RA. Are there<br />
any vaccines I cannot get<br />
NO!<br />
All vaccines (live, killed, attenuated) are safe in patients on nonchemotherapy<br />
doses of non-biologic DMARDs including:<br />
• methotrexate (< 0.5 mg/kg/wk)<br />
• hydroxychloroquine<br />
• leflunomide<br />
• azathioprine (< 3 mg/kg/day)<br />
Lacaille D, <strong>Arthritis</strong> Rheum. 2008.
I have been on Remicade<br />
(infliximab) for 5 years, can I<br />
get off of it
I have been on Remicade<br />
(infliximab) for 5 years, can I<br />
get off of it<br />
Maybe… it’s worth a try.
When biologic discontinued after remission achieved:<br />
• Sustained remission in 50-70% of patients, 2-7<br />
years after stopping infliximab<br />
• Best predictors of sustained remission are early<br />
treatment with and response to biologics<br />
• My empiric approach: taper off biologic once<br />
sustained clinical remission achieved by cutting<br />
dose in ½, increasing interval between doses<br />
van den Broek, Ann Rheum Dis. 2011.<br />
Tanaka, Ann Rheum Dis. 2010.<br />
Van der Kooij, Ann Rheum Dis. 2009.
I have viral hepatitis and<br />
seropositive (RF+/CCP+)<br />
rheumatoid arthritis. Is it safe<br />
to start Humira (adalimumab)<br />
A. OK to treat with anti-TNF in hepatitis B<br />
B. OK to treat with anti-TNF in hepatitis C<br />
C. OK to treat with anti-TNF in hepatitis B and C<br />
D. Not OK to treat with anti-TNF in hepatitis B or C
I have viral hepatitis and<br />
seropositive (RF+/CCP+)<br />
rheumatoid arthritis. Is it safe<br />
to start Humira (adalimumab)<br />
A. OK to treat with anti-TNF in hepatitis B<br />
B. OK to treat with anti-TNF in hepatitis C<br />
C. OK to treat with anti-TNF in hepatitis B and C<br />
D. not OK to treat with anti-TNF in hepatitis B or C
Anti-TNF’s are safe in hep C, not hep B<br />
• anti-TNF’s do not increase LFT’s or hep C viral load<br />
• anti-TNF’s can be started before or during anti-viral<br />
therapy for hepatitis C<br />
• anti-TNF’s delay the clearance of hep B<br />
• anti-TNF’s may lead to reactivation of latent hep B<br />
• all HBsAg+ patients should receive antiviral<br />
therapy prior to or together with the initiation of<br />
immunosuppressive therapy<br />
J Hepatol 2009.<br />
Roux CH, Rheumatology. 2006.<br />
Peterson JR, Ann Rheum Dis. 2003.
Take Home Messages<br />
1. Smoking increases risk and severity of RA<br />
2. Anti-TNF’s have definite risk of skin cancer and infection,<br />
possible risk of lymphoma or solid tumors<br />
3. Make sure patient is PPD negative before starting biologic<br />
4. No live viral vaccines for patients on biologics<br />
5. Anti-TNF’s are safe in active hepatitis C, not active hepatitis B